Treatment options for managing obesity in chronic kidney disease.
Journal
Current opinion in nephrology and hypertension
ISSN: 1473-6543
Titre abrégé: Curr Opin Nephrol Hypertens
Pays: England
ID NLM: 9303753
Informations de publication
Date de publication:
01 09 2021
01 09 2021
Historique:
pubmed:
28
5
2021
medline:
26
11
2021
entrez:
27
5
2021
Statut:
ppublish
Résumé
Obesity is a risk factor for the development and progression of chronic kidney disease (CKD). In this review, we provide a comprehensive overview of various management options (lifestyle intervention, medications, and bariatric surgery) to address obesity in those with CKD. Few clinical trials have examined the benefits of lifestyle modifications in those with preexisting CKD and suggest potential renal and cardiovascular benefits in this population. Yet, superiority of different dietary regimen to facilitate weight loss in CKD is unclear. Although medications could offer short-term benefits and assist weight loss, their safety and long-term benefits warrant further studies in this high-risk population. Observational studies report that bariatric procedures are associated with lower risk of end stage kidney disease. Clinicians should also recognize the higher risk of acute kidney injury, nephrolithiasis, and other complications noted with bariatric surgical procedures. Lifestyle modifications and some weight loss medications may be recommended for facilitating weight loss in CKD. Referral to bariatric centers should be considered among morbidly obese adults with CKD.
Identifiants
pubmed: 34039849
doi: 10.1097/MNH.0000000000000727
pii: 00041552-202109000-00008
pmc: PMC8373688
mid: NIHMS1704059
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
516-523Subventions
Organisme : HSRD VA
ID : I01 HX002917
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK101500
Pays : United States
Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet 2018; 392:2052–2090.
Ogden CL, Fryar CD, Martin CB, et al. Trends in obesity prevalence by race and Hispanic origin–1999–2000 to 2017–2018. JAMA 2020; 324:1208–1210.
Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies. Lancet 2009; 373:1083–1096.
Hsu CY, McCulloch CE, Iribarren C, et al. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006; 144:21–28.
Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 2014; 129:S102–S138.
Whaley-Connell A, Sowers JR. Obesity and kidney disease: from population to basic science and the search for new therapeutic targets. Kidney Int 2017; 92:313–323.
Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010; 316:129–139.
Sharma K, Ramachandrarao S, Qiu G, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008; 118:1645–1656.
Navaneethan SD, Kirwan JP, Remer EM, et al. Adiposity, physical function, and their associations with insulin resistance, inflammation, and adipokines in CKD. Am J Kidney Dis 2021; 77:44–55.
Elsayed EF, Tighiouart H, Weiner DE, et al. Waist-to-hip ratio and body mass index as risk factors for cardiovascular events in CKD. Am J Kidney Dis 2008; 52:49–57.
Navaneethan SD, Schold JD, Arrigain S, et al. Body mass index and causes of death in chronic kidney disease. Kidney Int 2016; 89:675–682.
Kramer H, Gutiérrez OM, Judd SE, et al. Waist circumference, body mass index, and ESRD in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study. Am J Kidney Dis 2016; 67:62–69.
Chintam K, Chang AR. Strategies to treat obesity in patients with CKD. Am J Kidney Dis 2021; 77:427–439.
Conley MM, McFarlane CM, Johnson DW, et al. Interventions for weight loss in people with chronic kidney disease who are overweight or obese. Cochrane Database Syst Rev 2021; 3:Cd013119.
Hu EA, Coresh J, Anderson CAM, et al. Adherence to healthy dietary patterns and risk of CKD progression and all-cause mortality: findings from the CRIC (Chronic Renal Insufficiency Cohort) study. Am J Kidney Dis 2021; 77:235–244.
Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369:145–154.
Look AHEAD Research Group. Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 2014; 2:801–809.
Ikizler TA, Robinson-Cohen C, Ellis C, et al. Metabolic effects of diet and exercise in patients with moderate to severe CKD: a randomized clinical trial. J Am Soc Nephrol 2018; 29:250–259.
Navaneethan SD, Zoungas S, Caramori ML, et al. Diabetes management in chronic kidney disease: synopsis of the 2020 KDIGO clinical practice guideline. Ann Intern Med 2021; 174:385–394.
Ikizler TA, Burrowes JD, Byham-Gray LD, et al. KDOQI clinical practice guideline for nutrition in CKD: 2020 update. Am J Kidney Dis 2020; 76:S1–S107.
Beddhu S, Wei G, Marcus RL, et al. Light-intensity physical activities and mortality in the United States general population and CKD subpopulation. Clin J Am Soc Nephrol 2015; 10:1145–1153.
Sharretts J, Galescu O, Gomatam S, et al. Cancer risk associated with lorcaserin – the FDA's review of the CAMELLIA-TIMI 61 trial. N Engl J Med 2020; 383:1000–1002.
Maalouf NM, Langston JP, Van Ness PC, et al. Nephrolithiasis in topiramate users. Urol Res 2011; 39:303–307.
Mann JFE, Ørsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017; 377:839–848.
Yerevanian A, Soukas AA. Metformin: mechanisms in human obesity and weight loss. Curr Obes Rep 2019; 8:156–164.
Aroda VR, Knowler WC, Crandall JP, et al. Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. Diabetologia 2017; 60:1601–1611.
Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:2295–2306.
Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021; 384:989.
Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA 2016; 315:2424–2434.
Arterburn DE, Telem DA, Kushner RF, Courcoulas AP. Benefits and risks of bariatric surgery in adults: a review. JAMA 2020; 324:879–887.
Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes – 5-year outcomes. N Engl J Med 2017; 376:641–651.
English WJ, DeMaria EJ, Hutter MM, et al. American Society for Metabolic and Bariatric Surgery 2018 estimate of metabolic and bariatric procedures performed in the United States. Surg Obes Relat Dis 2020; 16:457–463.
Sheetz KH, Gerhardinger L, Dimick JB, Waits SA. Bariatric surgery and long-term survival in patients with obesity and end-stage kidney disease. JAMA Surg 2020; 155:581–588.
Chang AR, Chen Y, Still C, et al. Bariatric surgery is associated with improvement in kidney outcomes. Kidney Int 2016; 90:164–171.
Shulman A, Peltonen M, Sjöström CD, et al. Incidence of end-stage renal disease following bariatric surgery in the Swedish Obese Subjects Study. Int J Obes (Lond) 2018; 42:964–973.
Alkharaiji M, Anyanwagu U, Donnelly R, Idris I. Effect of bariatric surgery on diagnosed chronic kidney disease and cardiovascular events in patients with insulin-treated type 2 diabetes: a retrospective cohort study from a Large UK Primary Care Database. Obes Surg 2020; 30:1685–1695.
Friedman AN, Wahed AS, Wang J, et al. Effect of bariatric surgery on CKD risk. J Am Soc Nephrol 2018; 29:1289–1300.
Turgeon NA, Perez S, Mondestin M, et al. The impact of renal function on outcomes of bariatric surgery. J Am Soc Nephrol 2012; 23:885–894.
Mishra T, Shapiro JB, Ramirez L, et al. Nephrolithiasis after bariatric surgery: a comparison of laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy. Am J Surg 2020; 219:952–957.
Kassam AF, Mirza A, Kim Y, et al. Long-term outcomes in patients with obesity and renal disease after sleeve gastrectomy. Am J Transplant 2020; 20:422–429.